{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-26-000030","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.547894+00:00","generated_at":"2026-05-15T09:34:36.097670+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial","bullets":["FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).","Sold Erivedge royalty assets for $2.5M upfront and liability release; recognized $27.2M non-cash gain in Q4.","Cash $5.1M at Dec 31; Jan 2026 PIPE raised $20.2M initial, up to $20.2M more from Series B warrants; runway into H2 2027.","Initiated Phase 2 CLL study of emavusertib + zanubrutinib; PCNSL trial: 100% ORR in BTKi-naïve (5/5) patients.","AML triplet study: 62.5% of patients (5/8) achieved MRD conversion to undetectable after adding emavusertib to aza-ven."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-26-000030","json":"https://secwatch.observer/filing/0001108205-26-000030.json","markdown":"https://secwatch.observer/filing/0001108205-26-000030.md","text":"https://secwatch.observer/filing/0001108205-26-000030.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/cris-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:34:36.097670+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7765835bc7a22b209b7dc5592af253793f6255ec","claim":"CURIS INC reported Fourth Quarter 2025 results: revenue $1.1 million, net income $19.4 million, EPS $1.23.","evidence_excerpt":"for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge ® . Revenues were $1.1 million and $3.3 million for the fourth quarters of 2025 and 2024, respectively. As previously announced, on November 6, 2025, the Company sold to TPC Investments Royalty LLC, a limited","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Fourth Quarter 2025"},{"label":"Revenue","value":"$1.1 million"},{"label":"Net income","value":"$19.4 million"},{"label":"EPS","value":"$1.23"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f5e8b716418d5eae2649e0e135411d455c443468","claim":"CURIS INC reported Year ended December 31, 2025 results: revenue $9.4 million, net income $7.6 million, EPS $0.58.","evidence_excerpt":"per share on both a basic and diluted basis as compared to a net loss of $9.6 million or $1.25 on both a basic and diluted basis for the same period in 2024. Revenues, net were $9.4 million and $10.9 million for the years ended December 31, 2025 and 2024, respectively. Revenues are comprised of royalty revenues related to Genentech and Roche's net sales of Erivedge","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/0001108205-26-000030-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Year ended December 31, 2025"},{"label":"Revenue","value":"$9.4 million"},{"label":"Net income","value":"$7.6 million"},{"label":"EPS","value":"$0.58"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}